Tagrisso is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor used to treat non-small-cell lung carcinomas with specific mutations.
We created an iOS application that utilizes 3 modules in order to establish Tagrisso as the preferential option in first line therapy while highlighting the results of a particular study.
• The first module, the Leakage Funnel Simulator, highlights the number of patients that will never benefit from Tagrisso through input from physicians’ clinical practice.
• The second module, Therapeutic sequencing, highlights the loss of benefit through alternative treatments with an overview of results among the different therapeutic options for the 1L.
• The third module, Post-Progression outcomes, serves to help physicians to overcome the question: “What to do next?” while focusing on first subsequent therapies and the results of the study this application was meant to